Mark Brody

3.8k total citations
14 papers, 371 citations indexed

About

Mark Brody is a scholar working on Physiology, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Mark Brody has authored 14 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 4 papers in Pharmacology and 3 papers in Psychiatry and Mental health. Recurrent topics in Mark Brody's work include Alzheimer's disease research and treatments (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Mark Brody is often cited by papers focused on Alzheimer's disease research and treatments (5 papers), Cholinesterase and Neurodegenerative Diseases (4 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). Mark Brody collaborates with scholars based in United States, Sweden and Belgium. Mark Brody's co-authors include Deborah L. Mortensen, Sharon Cohen, Flávia Brunstein, David Clayton, Robert Paul, Christopher H. van Dyck, Yong‐Yeon Cho, Christina Rabe, Carole Ho and Michel Friesenhahn and has published in prestigious journals such as Neurology, Stroke and The FASEB Journal.

In The Last Decade

Mark Brody

14 papers receiving 365 citations

Peers

Mark Brody

PHYSI

PMH

PHARM

EPIDE

Françoise Gerber Switzerland

Emma L. Ashby United Kingdom

Christopher Reardon United States

Carmen Castrillo‐Viguera United States

Aikaterini Anastasiou Greece

Michael Ouk Canada

C. Rosenberg United States

Guro Berge Norway

Felecia M. Marottoli United States

Raymond Klein United States

Françoise Gerber Switzerland

Mark Brody

348 ×1.6

PHYSI

83 ×0.9

PMH

122 ×1.4

PHARM

128 ×1.8

52 ×0.9

EPIDE

Citations per year, relative to Mark Brody Mark Brody (= 1×) peers Françoise Gerber

Countries citing papers authored by Mark Brody

Since Specialization

Citations

This map shows the geographic impact of Mark Brody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Brody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Brody more than expected).

Fields of papers citing papers by Mark Brody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Brody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Brody. The network helps show where Mark Brody may publish in the future.

Co-authorship network of co-authors of Mark Brody

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Brody. A scholar is included among the top collaborators of Mark Brody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Brody. Mark Brody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ramdas, Kevin, Joshua M. Hare, Jeffrey L. Cummings, et al.. (2024). Results from a Phase 2a Proof‐of‐Concept Double‐Blind, Randomized, Placebo‐Controlled Trial of Lomecel‐B^TM in Mild Alzheimer’s Disease Dementia. Alzheimer s & Dementia. 20(S6). 1 indexed citations

Brody, Mark, Marc Agronin, Susan Y. Bookheimer, et al.. (2022). Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease. Alzheimer s & Dementia. 19(1). 261–273. 39 indexed citations

Oliva, Anthony A., Mark Brody, Marc Agronin, et al.. (2020). Clinical evaluation of allogeneic mesenchymal stem cells for Alzheimer's disease. Alzheimer s & Dementia. 16(S9). 1 indexed citations

Oliva, Anthony A., Mark Brody, Marc Agronin, et al.. (2019). P2‐039: PROGRESS OF THE PHASE I CLINICAL TRIAL TO EVALUATE LONGEVERON ALLOGENEIC MESENCHYMAL STEM CELLS (LMSCS) AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 15(7S_Part_11). 1 indexed citations

Cummings, Jeffrey L., Sharon Cohen, Christopher H. van Dyck, et al.. (2018). ABBY. Neurology. 90(21). e1889–e1897. 182 indexed citations

Brody, Mark, Enchi Liu, Jianing Di, et al.. (2016). A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease. Journal of Alzheimer s Disease. 54(4). 1509–1519. 27 indexed citations

Stein, Richard A., et al.. (2016). Open label, crossover, pilot study to assess the efficacy and safety of perispinal administration of etanercept (Enbrel ^® ) in combination with nutritional supplements versus nutritional supplements alone in subjects with mild to moderate Alzheimer's disease receiving standard care. The FASEB Journal. 30(S1). 1 indexed citations

Coric, Vlad, Stephen Salloway, Christopher van Dyck, et al.. (2013). P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease. Alzheimer s & Dementia. 9(4S_Part_7). 8 indexed citations

Salloway, Stephen, Vlad Coric, Mark Brody, et al.. (2011). O4‐06‐08: Safety and tolerability of BMS‐708163 in a phase II study in mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 7(4S_Part_20). 4 indexed citations

10.

Coric, Vlad, John Seibyl, Mark A. Mintun, et al.. (2011). P1‐309: Correlation between baseline measures of amyloid‐positron emission tomography (PET) imaging, cerebral spinal fluid (CSF) biomarkers, and clinical scales in predementia Alzheimer's disease. Alzheimer s & Dementia. 7(4S_Part_6). 1 indexed citations

11.

Raskind, Murray A., Earvin Liang, Reisa Sperling, et al.. (2009). P3‐246: Pharmacokinetics and pharmacodynamics of bapineuzumab following multiple intravenous infusions in patients with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 5(4S_Part_14). 2 indexed citations

12.

Zweifler, Richard M., et al.. (1998). Intravenous t‐PA for acute ischemic stroke. Neurology. 50(2). 501–503. 37 indexed citations

13.

Zweifler, Richard M., et al.. (1997). Implementation of a Stroke Code System in Mobile, Alabama. Stroke. 28(5). 981–983. 27 indexed citations

14.

Brody, Mark, et al.. (1994). Validation of a new instrument for determining migraine prevalence. Neurology. 44(5). 925–925. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact